| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/25/2007 | CA2614327A1 Use of thiazole derivatives and analogues in disorders caused by free fatty acids |
| 01/25/2007 | CA2614187A1 Drospirenone containing transdermal drug delivery devices and methods of delivery thereof |
| 01/25/2007 | CA2613178A1 Sustained release preparation |
| 01/25/2007 | CA2612960A1 Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate |
| 01/25/2007 | CA2612604A1 Purification of paricalcitol |
| 01/25/2007 | CA2612599A1 Precursor compounds to antiarrhythmic benzolfuran compounds, methods of synthesis and methods of use |
| 01/25/2007 | CA2612482A1 Biologically active compounds obtainable from sorangium cellulosum |
| 01/25/2007 | CA2612469A1 Benzimidazole derivatives for treatment of inflammatory diseases |
| 01/25/2007 | CA2612468A1 4,5-dihydr0-1h-pyrazole derivatives, their preparation and use as medicaments |
| 01/25/2007 | CA2612459A1 New crystal forms of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide |
| 01/25/2007 | CA2611598A1 Jnk inhibitors for the treatment of endometriosis |
| 01/25/2007 | CA2611366A1 Azepane- or azocane-substituted pyrazoline derivatives, their preparation and use as medicaments |
| 01/25/2007 | CA2611364A1 Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments |
| 01/25/2007 | CA2609929A1 Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders |
| 01/25/2007 | CA2607360A1 Solid dosage formulations of narcotic drugs having improved buccal adsorption |
| 01/24/2007 | EP1746701A1 Intelligent serial battery charger |
| 01/24/2007 | EP1746159A2 Immunostimulatory nucleic acid molecules |
| 01/24/2007 | EP1746157A1 Method of proliferating plasma cell |
| 01/24/2007 | EP1746108A1 Fish-origin chondroitin sulfate/dermatan sulfate hybrid chain |
| 01/24/2007 | EP1746100A1 Annelated carbamoylase-heterocycles, focused library, pharmaceutical compositions and methods for the production thereof |
| 01/24/2007 | EP1746099A1 Mnk1 or Mnk2 inhibitors |
| 01/24/2007 | EP1746098A1 Valacyclovir polymorphs and a process for the preparation thereof |
| 01/24/2007 | EP1746097A1 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them |
| 01/24/2007 | EP1746096A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer |
| 01/24/2007 | EP1746095A1 Indanol derivative |
| 01/24/2007 | EP1746093A1 Process for preparing substituted pyrimidines |
| 01/24/2007 | EP1746092A1 Compounds and methods for treatment of amyloid-B-peptide related disorders |
| 01/24/2007 | EP1746087A1 Derivates of 3-indolylmethylene having cytostatic properties |
| 01/24/2007 | EP1746086A1 Cyanopyrrolidine derivatives |
| 01/24/2007 | EP1746082A1 Salts of zinc and aliphatic haloid carboxylic acids for therapy of skin neoplasms and visible mucous coats |
| 01/24/2007 | EP1745800A1 Novel blt2-mediated disease, and blt2 binding agent and compound |
| 01/24/2007 | EP1745799A2 Compositions and methods of treating tumors |
| 01/24/2007 | EP1745797A2 Vascularization inhibitors |
| 01/24/2007 | EP1745796A1 Compound preparation for treating prostate carcinoma |
| 01/24/2007 | EP1745791A2 Treating cartilage/bone conditions with water-soluble strontium salts |
| 01/24/2007 | EP1745790A2 Treatment of rumen acidosis with alpha-amylase inhibitors |
| 01/24/2007 | EP1745789A1 Compositions comprising ribose for increasing energy in vivo |
| 01/24/2007 | EP1745788A1 Acyglycerophospholipids for treating cancer and cachexia |
| 01/24/2007 | EP1745787A2 Non-calcemic, antiproliferative, transcriptionally active sulfur-containing analogs of 1-alpha 25-dihydroxy Vitamin D3 |
| 01/24/2007 | EP1745786A1 Neuroprotective compounds and pharmaceutical compositions comprising them |
| 01/24/2007 | EP1745785A1 Pharmaceutical composition for preventing or treating cerebral oedema |
| 01/24/2007 | EP1745784A1 Oxazolidinone derivatives and use thereof as antibiotics |
| 01/24/2007 | EP1745783A1 Substituted pyrazoline compounds, their preparation and use as medicaments |
| 01/24/2007 | EP1745782A1 Use of substitued pyrazoline compounds for the preparation of medicaments for the treatment of metabolic syndrome |
| 01/24/2007 | EP1745781A1 Combination of pyrazoline type cannabinoid receptor antagonist and statin |
| 01/24/2007 | EP1745780A1 Medicinal preparation |
| 01/24/2007 | EP1745779A2 Uses of perfluorinated carboylic acid derivatives for the manufacture of a medicament for the modulation of body mass |
| 01/24/2007 | EP1745778A2 Diaminoalcohols as therapeutic compounds |
| 01/24/2007 | EP1745777A1 Amido-aminoalcohols as therapeutic compounds |
| 01/24/2007 | EP1745776A1 Aminoalcohols as therapeutic compounds |
| 01/24/2007 | EP1745774A2 Solid pharmaceutical dispersions with enhanced bioavailability |
| 01/24/2007 | EP1745705A1 Process for preparing uronic acid oligosaccharides by extrusion |
| 01/24/2007 | EP1745194A2 Methods for diagnosing and treating bladder cancer |
| 01/24/2007 | EP1745135A1 Topical regulation of triglyceride metabolism |
| 01/24/2007 | EP1745127A2 Methods for regulating differentiation of neural cells and uses thereof |
| 01/24/2007 | EP1745069A2 Therapeutic use of a growth factor, nsg33 |
| 01/24/2007 | EP1745061A1 Novel amphiphilic compounds, preparation method thereof and applications of same |
| 01/24/2007 | EP1745060A2 Compounds for treating alzheimer's disease and for inhibiting beta-amyloid peptide production |
| 01/24/2007 | EP1745054A2 Dealkylated derivatives of pyrrolo(2,1-b)benzothiazepines with atypical antipsychotic activity |
| 01/24/2007 | EP1745053A1 Trihemihydrate, anhydrate and hydrate forms of cefdinir |
| 01/24/2007 | EP1745052A1 Hiv integrase inhibitors: cyclic pyrimidinone compounds |
| 01/24/2007 | EP1745051A1 Thienopyridazines as ikk inhibitors |
| 01/24/2007 | EP1745050A1 Thienopyridines as ikk inhibitors |
| 01/24/2007 | EP1745047A1 Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists |
| 01/24/2007 | EP1745046A2 1 h-indazoles, benzothiazoles, 1,2-benziosoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof |
| 01/24/2007 | EP1745045A2 NOVEL DICATIONIC IMIDAZO 1,2-a PYRIDINES AND 5,6,7,8-TE TRAHYDRO-IMIDAZO 1,2a PYRIDINES AS ANTIPROTOZOAL AGENTS |
| 01/24/2007 | EP1745044A2 Benzothiazole derivatives having cdk modulating activity and use thereof as anticancer agents |
| 01/24/2007 | EP1745042A1 Diarylamine derivatives as calcium channel blockers |
| 01/24/2007 | EP1745041A2 Quinoxaline inhibitors of the hedgehog signalling pathway |
| 01/24/2007 | EP1745040A1 Azabicyclo(3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors |
| 01/24/2007 | EP1745039A2 3-aryl-5,6-disubstituted pyridazines |
| 01/24/2007 | EP1745036A2 Cytokine inhibitors |
| 01/24/2007 | EP1745035A1 Polymorphic and amorphous forms of 2,5-dimethyl-2h-pyrazole-3-carboxylic acid-{2-fluoro-5-¬3-((e)-2-pyridin-2-ylvinyl)-1h-indazol-6-ylamino|-phenyl}-amide |
| 01/24/2007 | EP1745034A1 Vanilloid receptor ligands and their use in treatments |
| 01/24/2007 | EP1745033A2 4,5-disubstituted-2-aryl pyrimidines |
| 01/24/2007 | EP1745032A2 Cxcr1 and cxcr2 chemokine antagonists |
| 01/24/2007 | EP1745031A1 Crystalline forms of duloxetine free base |
| 01/24/2007 | EP1745029A1 Substituted morpholine compounds for the treatment of central nervous system disorders |
| 01/24/2007 | EP1745028A2 Solid forms of linezolid and processes for preparation thereof |
| 01/24/2007 | EP1745026A1 Cationic dyes and dyestuff for keratin fibres, containing said compounds |
| 01/24/2007 | EP1745024A1 1-aryl-4-substituted isoquinolines |
| 01/24/2007 | EP1745022A1 Histone deacetylase inhibitor prodrugs |
| 01/24/2007 | EP1745020A2 Salt forms of atorvastatin |
| 01/24/2007 | EP1745019A1 Novel compounds of proline and morpholine derivatives |
| 01/24/2007 | EP1745015A1 Bicyclic aromatic sulfinyl derivatives |
| 01/24/2007 | EP1745012A2 Compositions of allosteric hemoglobin modifiers and methods of making the same |
| 01/24/2007 | EP1745011A2 Modulators of cannabinoid receptors |
| 01/24/2007 | EP1745010A1 Substituted cyclohexyl-1,4-diamine derivatives |
| 01/24/2007 | EP1745007A2 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents |
| 01/24/2007 | EP1745004A2 Aryl ketone compounds and compositions for delivering active agents |
| 01/24/2007 | EP1745003A1 Novel compounds, their preparation and use |
| 01/24/2007 | EP1745002A1 Novel compounds, their preparation and use |
| 01/24/2007 | EP1744788A2 Combinatorial methods and compositions for treatment of melanoma |
| 01/24/2007 | EP1744784A2 Formulations of anti-pain agents and methods of using the same |
| 01/24/2007 | EP1744781A1 Treatment of infectious diseases |
| 01/24/2007 | EP1744780A2 Cancer treatment using viruses and camptothecins |
| 01/24/2007 | EP1744775A1 Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency |
| 01/24/2007 | EP1744774A2 Nutritional composition which promotes weight loss, burns calories, increases thermogenesis, supports energy metabolism and/or suppresses appetite |
| 01/24/2007 | EP1744768A2 Peritoneal dialysis solution |
| 01/24/2007 | EP1744767A2 Therapeutic delivery system comprising a high molecular weight peg-like compound |